AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer's Disease

AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease Ongoing Phase 1b/2 ABATE study enrolling well and expanding to sites in USA with Investigational New Drug (IND) clearance for ACI-24.060Dosed first individual with Down syndrome (DS) in the DS cohort of ABATEInterim safety and immunogenicity data in Alzheimer’s disease (AD) and DS cohorts expected in H2 2023Initial PET data on amyloid plaque reduction in AD expected

Related Keywords

United States ,Switzerland ,Eli Lilly ,Corey Davis ,Chris Maggos ,Andrea Pfeifer ,Michael Rafii ,Gary Waanders ,Johannes Streffer ,Keck School Of Medicine ,Securities Exchange ,Drug Administration ,Roche Group ,International Media ,Head Of Investor Relations Corporate Communications ,Cohesion Bureau ,Alzheimer Therapeutic Research Institute ,Genentech ,Exchange Commission ,Fast Track Designation ,Treat Alzheimer ,Investigational New Drug ,Fast Track ,Medical Director ,Therapeutic Research Institute ,Keck School ,Principal Investigator ,Reviews Neurology ,Investor Relations ,Securities Act ,Securities Exchange Act ,Financial Review ,Annual Report ,